Malignant Mesotheliomas Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Chemotherapy, Radiation Therapy), By Disease Type (Pleural Mesothelioma, Peritoneal Mesothelioma), By Route of Administration (Oral, Intravenous), By End User (Hospitals, Oncology Clinics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), and Region Forecast 2020-2031

Malignant Mesotheliomas Market size was valued at US$ 1,250 million in 2024 and is projected to reach US$ 1,780 million by 2031 at a 5.2% CAGR from 2025-2031. Moreover, the U.S. Malignant Mesotheliomas Market is projected to grow significantly, reaching an estimated value of US$ 690 million by 2031.

The Global Malignant Mesotheliomas Market refers to the market encompassing products and services related to the diagnosis, treatment, and management of malignant mesothelioma — a rare, aggressive cancer primarily caused by asbestos exposure and affecting the lining of the lungs, abdomen, or heart. This market includes chemotherapy, immunotherapy, targeted therapy, surgery, and supportive care solutions, as well as diagnostic tools and research-based innovations aimed at improving patient survival and quality of life.

The market has been witnessing steady growth due to rising incidence rates linked to historical asbestos exposure and increasing awareness about early detection and advanced treatment options. Technological advancements in diagnostics and the introduction of novel targeted therapies have further fuelled market expansion. Additionally, growing healthcare expenditure, supportive government initiatives, and improved access to specialized cancer care centres contribute to market growth worldwide. Despite challenges related to high treatment costs and limited curative options, the market is projected to maintain a positive trajectory through 2031.

Facts & Figures

• Checkpoint inhibitors are reshaping first-line therapy: New regulatory approvals of immune checkpoint inhibitors for unresectable pleural mesothelioma are moving standard treatment protocols away from platinum chemotherapy.
• Diagnosis is lagging innovation: With increasing therapy, more than 70% of mesothelioma patients continue to be diagnosed at advanced stages, making them candidates neither for surgical therapy nor curative multimodal treatment.
• Biomarker-led trials are speeding up around the world: Adaptive trial platforms are enabling quicker recruitment for rare cancer trials, such as PD-L1 expression, BAP1 mutation, and tumor mutational burden trials.
• Asia-Pacific is becoming R&D hub: Increased incidence due to previous asbestos exposure and increased industry-academic cooperation are turning nations such as Japan and South Korea into leading drivers of mesothelioma research and trial activity.

Key Developments

• In April 2025, results from investigator-initiated Phase II NERO trial (NCT05455424) showed that GSK's Zejula (niraparib) reduced the risk of disease progression or death by 27% among patients with mesothelioma who previously received platinum-based treatment.
• In November 2023, Bristol-Myers Squibb K.K. and Ono Pharmaceutical obtained supplemental approval in Japan for Opdivo® (nivolumab IV) to treat malignant mesothelioma indications other than pleural mesothelioma, a regulatory first in non-pleural disease treatment.

Malignant Mesotheliomas Market Segmentation

Based on the treatment type

• Chemotherapy
• Radiation Therapy
• Surgery
• Immunotherapy
• Targeted therapy

Chemotherapy is still a mainstay modality of malignant mesothelioma treatment, mainly in those who have unresectable disease or who are not candidates for immunotherapy. Cisplatin and pemetrexed remain the most employed first-line regimen, based on decades of clinical experience and proven survival outcomes. Although not curative, it achieves modest control of progression and palliation of symptoms in pleural and peritoneal mesothelioma. Its versatility in geographically diverse healthcare environments and relatively lower price make chemotherapy the entry point of choice for most geographies. Significantly, it is also commonly employed as a backbone in multimodal treatment approaches, in association with surgery or radiotherapy, to improve treatment outcomes where necessary.

Based on the disease type

• Pleural Mesothelioma
• Peritoneal Mesothelioma
• Pericardial Mesothelioma
• Testicular Mesothelioma

Pleural mesothelioma, the most prevalent and commercially relevant subtype of disease in this group, affects the pleura overlying the lungs. It is responsible for almost 80% of all instances of malignant mesothelioma and can be diagnosed in many patients with an earlier history of occupational asbestos exposure. Its occurrence has spurred a disproportionately greater proportion of investigations, clinical trials, and approvals. Approved drug treatments, primarily checkpoint inhibitors nivolumab and ipilimumab, have been approved in first line for this subtype only, which is indicative of its priority in clinical and commercial approaches. Secondly, the anatomical complexity of pleural mesothelioma also provides it with an interesting prospect of surgical treatment and palliative care.

Based on the route of administration

• Oral
• Intravenous
• Injectable
• Topical

Intravenous administration remains the most widespread approach to malignant mesothelioma treatment because many of the chemotherapies and immunotherapies approved for use are parenteral in nature. Intravenous administration allows for maximum bioavailability, dosing control, and rapid systemic distribution, each of which is particularly required in the case of virulent neoplasms with complex growth patterns. It further provides for combination regimen infusion via outpatient status, reducing therapeutic effect variability. Beyond chemotherapy, nearly all leading immuno-oncology products available or under investigation for mesothelioma, such as PD-1 inhibitors, are available in IV formulation, further supporting the route's dominance in the market. While oral forms are being made in other areas of cancer, the clinical seriousness of mesothelioma maintains IV as the first choice for front-line and combination treatment.

Based on the end user

• Hospitals
• Oncology Clinics
• Rehabilitation Centers
• Research Laboratories

Hospitals are the treatment's main location for malignant mesothelioma because of the complexity, virulence, and coordinated, multidisciplinary nature of the disease. Patients are frequently in need of multidisciplinary care by pulmonologists, oncologists, thoracic surgeons, and palliative care specialists, resources best focused within hospital settings. Hospitals are also usually the site of initiation for immunotherapy infusions, inpatient chemotherapy, intensification of imaging, and surgery such as pleurectomy/decortication. They also conduct most mesothelioma-focused clinical trials, providing patients with immediate access to new therapies. The supportive care infrastructure demanded by procedures like drainage techniques, respiratory rehabilitation, and vigorous symptom management also places hospitals in the forefront of mesothelioma treatment management.

Based on the distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

Hospital pharmacies dominate the distribution channel for malignant mesothelioma medication, especially because of the presence of intravenous and high-value specialty drugs. These pharmacies are specifically designed to handle advanced cold-chain logistics, biologic inventory, and controlled delivery of immune checkpoint inhibitors and chemotherapy agents. They are integrated into tightly coupled clinical environments, where drug administration is immediately followed by patient monitoring protocols. This closed-loop architecture increases safety and efficacy, decreasing risk of off-schedule dosing or drug abuse. Moreover, hospital pharmacies are typically the organization of dispensing drug utilized under the research guidelines of clinical trials and thus are at the center point not only of the delivery of commercial care but also of research in cases of rare oncology.